arrow
Y

Yosuke Togashi

chiba cancer center research institute
H指数:49
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Molecular Characteristics and Clinical Outcomes of ERBB2-Activating Mutation-Positive Non-Small Cell Lung Cancer: A Japanese Nationwide Real-World Cohort

ERBB2激活突变阳性非小细胞肺癌的分子特征和临床结局:一项日本全国性真实世界队列研究

2026-09-290
OA
Efficacy and biomarker analysis for nivolumab in cancer of unknown primary: results from an investigator-initiated expanded access program

纳武利尤单抗治疗未知原发灶癌症的疗效与生物标志物分析:来自研究者发起的扩展性准入项目的结果

2026-09-240
OAAI
ULK1, a novel therapeutic target to delay drug tolerance to EGFR-TKIs in an EGFR-mutant non-small cell lung cancer model

ULK1作为EGFR突变非小细胞肺癌模型中延迟EGFR-TKIs药物耐受的新型治疗靶点

2026-07-010
PRE
Risk Factors for Waiting List Mortality in Lung Transplant Candidates With Post-Hematopoietic Stem Cell Transplantation Non-Infectious Pulmonary Complications

造血干细胞移植后非感染性肺部并发症患者等待移植期间死亡的危险因素

2026-05-280
PREAI
Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr-mutated lung cancer

干扰素基因刺激物激动剂增强了奥希替尼在EGFR突变型肺癌中的抗肿瘤免疫作用

2026-05-210
OAAI
Single-cell and spatial transcriptomic characterization of pulmonary pleomorphic carcinoma

单细胞和空间转录组学表征肺多形性癌

2025-12-160
OAAI
Endotracheal and Endobronchial Metastases in Epidermal Growth Factor Receptor Exon 19 Deletion Lung Adenocarcinoma: A Case Successfully Managed with Bronchoscopic Therapy and Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
2025-10-010
PRE
The efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in relation to tumor-infiltrating lymphocytes

阿特珠单抗联合贝伐珠单抗治疗晚期肝细胞癌的疗效与肿瘤浸润淋巴细胞的关系

2025-10-010
OAAI
Author Correction: Immune evasion through mitochondrial transfer in the tumour microenvironment

作者更正:肿瘤微环境中的线粒体转移介导的免疫逃逸

Nature
IF48.5
2025-07-250
OA